The Relationship Between Serum Neuron-Specific Enolase Levels and Severity of Bleeding and Functional Outcomes in Patients With Nontraumatic Subarachnoid Hemorrhage

Abstract

We found a significant association between higher NSE levels and poorer clinical presentations and worse outcomes. Although it is still early for any relevant clinical conclusions, our results suggest that NSE holds promise as a tool for screening patients at increased risk of poor outcomes after SAH.

S100B, NSE and MMP-9 fail to predict neurologic outcome while elevated S100B associates with milder initial clinical presentation after aneurysmal subarachnoid hemorrhage

“…They used only the first NSE measurement for each patient in the analysis. Timepoints in which measurements were made varied between patients making it difficult to conclude the temporal profile of NSE levels [30].…”

Neuron specific enolase: a promising therapeutic target in acute spinal cord injury

“…Like TBI, ischemia, and ICH, NSE levels are increased in subarachnoid hemorrhage (SAH) patients. Using 71 patients, a significant association between higher levels of NSE and worse outcomes has recently been reported [72], suggesting that NSE may hold promise for screening SAH patients.…”

Can we improve the prediction of complications and outcome in aneurysmal subarachnoid hemorrhage? The clinical implications of serum proteomics

“…Kacira et al (2007) and colleagues demonstrated an increasing level of serum NSE towards day 7 in 20 patients having aSAH, with values reaching 18.54 ± 19.86 µg/L compared with 5.94 ± 2.20 µg/L in a control group, and this was attributed to increased neuronal damage. Furthermore, Tawk et al (2016) and colleagues involved 309 patients. They found that NSE level > 15 ng/mL is considered relatively high and significantly associated with higher WFNS score, GCS, and H&H grade, concluding that NSE can be a potential predictor for poor outcome in aSAH.…”